Trial of split-product trivalent influenza vaccine in high-risk children.
Split-product trivalent influenza vaccine, containing H3N2, H1N1 and B, was given to 188 high-risk children and 25 healthy ones in the 4 year period from 1978 to 1981. A field trial involving 80 of these children was performed for evaluating the safety and immunogenicity of this vaccine. The antibody response to influenza vaccine in the patients was similar to that in normal children. The reaction to this vaccine of high-risk children was low, and no severe clinical reactions were observed after vaccination.